跳至主要内容
临床试验/NL-OMON48994
NL-OMON48994已完成2 期

PRACTICAL study: Pharmaco-enhancement in Rheumatoid Arthritis with Cobicistat to dose Tofacitinib In Clinic Adequately Low. A within-subject sequential study. - PRACTICA

Radboud Universitair Medisch Centrum0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
入组人数
30

研究概览

简要总结

Trial is onging in other countries

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • * Rheumatoid arthritis (either 2010 ACR RA and/or 1987 RA criteria and/or
  • clinical diagnosis of the treating rheumatologist, fulfilled at any time point
  • between start of the disease and inclusion) or Psoriatic arthritis (either
  • Classification Criteria for Psoriatic Arthritis (CASPAR) and/or diagnosed with
  • peripheral SpA of the psoriatic arthritis subtype by a rheumatologist)
  • * Patients using tofacitinib for * 2 weeks in the standard dose of 5mg BID.
  • * Patient informed consent, *18 years old and mentally competent
  • * Ability to measure the outcome of the study in this patient (e.g. patient
  • availability; willing and being able to undergo repeated serum samples)
  • * Ability to read and communicate well in Dutch

排除标准

  • * Concomitant use of inducers or potent inhibitors of CYP3A4 or moderate
  • inhibitors of CYP3A4 and potent inhibitors of CYP2C19, or medication sensitive
  • to changes in metabolism as a result of cobicistat co-treatment, as assessed
  • with the KNMP *G-standaard* unless an alternative is listed in Table 1.
  • * Known contra-indications for treatment with cobicistat in line with the
  • summary of product characteristics

研究者

相似试验